Sonia Gandhi | |
---|---|
Alma mater | |
Scientific career | |
Fields | Protein misfolding Neurodegeneration Parkinson's disease |
Institutions |
|
Thesis | The role of PINK1 in Parkinson's disease (2009) |
Website | www |
Sonia Gandhi is a British physician and neuroscientist who leads the Francis Crick Institute neurodegeneration laboratory.[1][2] She holds a joint position at the UCL Queen Square Institute of Neurology. Her research investigates the molecular mechanisms that give rise to Parkinson's disease. During the COVID-19 pandemic, Gandhi was involved with the epidemiological investigations and testing efforts at the Francis Crick Institute.
Gandhi studied neuroscience at Trinity College, Cambridge, and earned her bachelor's degree in 1996.[3][4] She moved to the University of Oxford to complete a Bachelor of Medicine, Bachelor of Surgery (BM BCh) degree in medicine.[5] She was a trainee neurologist at the Hammersmith Hospital, National Hospital for Neurology and Neurosurgery and Whittington Hospital. In 2004 she was awarded a Wellcome Trust fellowship to work toward a doctoral degree in neuroscience at the UCL Queen Square Institute of Neurology, and completed her PhD in 2009.[6]
She was awarded a National Institute for Health Research (NIHR) lectureship at Imperial College London in 2009.[3] In 2012 she was awarded a Wellcome Trust intermediate clinical fellowship to study the misfolding of alpha-synuclein in Parkinson's disease, and how this misfolding causes neurotoxicity.[7] Gandhi established her laboratory at the UCL Queen Square Institute of Neurology in 2013.[8] Her research group develop human-derived induced pluripotent stem cell (iPSC) models of disease, with a focus on understanding how the aggregation of alpha-synuclein, a protein encoded by the SNCA gene, impacts cell physiology.[8] She makes use of single-molecule FRET and mitochondrial physiology to study the behaviour of alpha-synuclein at the molecular level.[7]
In 2016 Gandhi was awarded a secondment at the Francis Crick Institute.[9] Gandhi and co-workers showed that clumps of alpha-synuclein can be toxic to neural function, damaging proteins on the surface of mitochondria.[10][11] This damage forced a channel on mitochondria to open and made them less efficient in their production of energy, causing them to swell and leak essential chemicals – eventually causing the cell to die.[10] To perform the experiments, Gandhi and colleagues turned human skin cells into stem cells, which were converted into brain cells that could be investigated into the laboratory.[10] She was part of a team who investigated the use of exenatide as a means to slow the progression of multiple system atrophy.[12] In February 2020 Gandhi was awarded a Medical Research Council (MRC) clinical fellowship to study the fundamental origins of Parkinson's disease.[13]
During the COVID-19 pandemic, Gandhi studied the epidemiology of coronavirus disease.[14] In particular, Gandhi was interested in how the virus evolved throughout the course of the pandemic, how it impacted the nervous system and how it was transmitted between people.[14] She was also involved with the COVID-19 testing that took place at the Francis Crick Institute.[15]
Gandhi's publications[1][2] include: